This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Rodriguez, J. Articles by Khouri, I. F. Search for Related Content PubMed PubMed Citation Articles by Rodriguez, J. Articles by Khouri, I. F. Social Bookmarking                            What's this?

Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas

From the Departments of Blood and Marrow Transplantation, Lymphoma, and Biomathematics, University of Texas M.D. Anderson Cancer Center, Houston, TX.

Address reprint requests to Issa F. Khouri, MD, Department of Blood and Marrow Transplantation, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Blvd, Box 423, Houston, TX 77030; email: ikhouri{at}notes.mdacc.tmc.edu

PURPOSE: To evaluate the outcome of high-dose chemotherapy (HDCT) and autologous or allogeneic hematopoietic transplantation in patients with peripheral T-cell lymphoma (PTCL) who experienced disease recurrence after prior conventional chemotherapy.

PATIENTS AND METHODS: We performed a retrospective analysis of 36 PTCL patients from the University of Texas M.D. Anderson Cancer Center treated between 1989 and 1998 with HDCT and autologous or allogeneic hematopoietic transplantation.

RESULTS: A total of 36 patients were studied (29 received autologous transplantation, and seven received allogeneic transplantation). The overall survival rate at 3 years was 36% (95% confidence interval [CI], 23% to 59%), and the progression-free survival (PFS) rate was 28% (95% CI, 16% to 49%). The pretransplant serum lactate dehydrogenase level was the most important prognostic factor for both survival and PFS rates (P < .001). A Pretransplant International Prognostic Index score of 1 indicated a superior survival rate (P = .036) but not an improved PFS rate. A median follow-up of 43 months (range, 13 to 126 months) showed 13 patients (36%) were still alive with no evidence of disease.

CONCLUSION: Our results are comparable to the published data on HDCT in B-cell non-Hodgkin’s lymphoma (NHL) patients despite the fact that patients with PTCL are known to have a worse outcome compared with B-cell NHL patients. Considering the dismal outcome of conventional chemotherapy in PTCL patients, these data suggest the hypothesis that the poor prognostic implication of T-cell phenotyping in NHL might be overcome by frontline HDCT and transplantation.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. J. Moskowitz and C. H. Moskowitz Controversies in the Treatment of Lymphoma with Autologous Transplantation Oncologist, September 1, 2009; 14(9): 921 - 929. [Abstract] [Full Text] [PDF]

				P. Reimer, T. Rudiger, E. Geissinger, F. Weissinger, C. Nerl, N. Schmitz, A. Engert, H. Einsele, H. K. Muller-Hermelink, and M. Wilhelm Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study J. Clin. Oncol., January 1, 2009; 27(1): 106 - 113. [Abstract] [Full Text] [PDF]

				International T-Cell Lymphoma Project International Peripheral T-Cell and Natural Killer/T-Cell Lymphoma Study: Pathology Findings and Clinical Outcomes J. Clin. Oncol., September 1, 2008; 26(25): 4124 - 4130. [Abstract] [Full Text] [PDF]

				S. Le Gouill, N. Milpied, A. Buzyn, R. Peffault De Latour, J.-P. Vernant, M. Mohty, M.-P. Moles, K. Bouabdallah, C.-E. Bulabois, J. Dupuis, et al. Graft-Versus-Lymphoma Effect for Aggressive T-Cell Lymphomas in Adults: A Study by the Societe Francaise de Greffe de Moelle et de Therapie Cellulaire J. Clin. Oncol., May 10, 2008; 26(14): 2264 - 2271. [Abstract] [Full Text] [PDF]

				C. Kyriakou, C. Canals, A. Goldstone, D. Caballero, B. Metzner, G. Kobbe, H.-J. Kolb, J. Kienast, P. Reimer, J. Finke, et al. High-Dose Therapy and Autologous Stem-Cell Transplantation in Angioimmunoblastic Lymphoma: Complete Remission at Transplantation Is the Major Determinant of Outcome--Lymphoma Working Party of the European Group for Blood and Marrow Transplantation J. Clin. Oncol., January 10, 2008; 26(2): 218 - 224. [Abstract] [Full Text] [PDF]

				A. Gallamini, F. Zaja, C. Patti, A. Billio, M. R. Specchia, A. Tucci, A. Levis, A. Manna, V. Secondo, L. Rigacci, et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial Blood, October 1, 2007; 110(7): 2316 - 2323. [Abstract] [Full Text] [PDF]

				J. Rodriguez, E. Conde, A. Gutierrez, J. J. Lahuerta, R. Arranz, A. Sureda, J. Zuazu, A. F. de Sevilla, M. Bendandi, C. Solano, et al. The adjusted International Prognostic Index and {beta}-2-microglobulin predict the outcome after autologous stem cell transplantation in relapsing/refractory peripheral T-cell lymphoma Haematologica, August 1, 2007; 92(8): 1067 - 1074. [Abstract] [Full Text] [PDF]

				J Rodriguez, E Conde, A Gutierrez, R Arranz, A Leon, J Marin, M Bendandi, C Albo, M. Caballero, and On behalf of the Grupo Espanol de Linfomas/Traspla The results of consolidation with autologous stem-cell transplantation in patients with peripheral T-cell lymphoma (PTCL) in first complete remission: the Spanish Lymphoma and Autologous Transplantation Group experience Ann. Onc., April 1, 2007; 18(4): 652 - 657. [Abstract] [Full Text] [PDF]

				M. A. Rizvi, A. M. Evens, M. S. Tallman, B. P. Nelson, and S. T. Rosen T-cell non-Hodgkin lymphoma Blood, February 15, 2006; 107(4): 1255 - 1264. [Abstract] [Full Text] [PDF]

				G. Tisdale, A. Mahadevan, and R. H. Matthews T-Cell Lymphoma of the Rectum in a Patient with AIDS and Hepatitis C: A Case Report and Discussion Oncologist, April 1, 2005; 10(4): 292 - 298. [Abstract] [Full Text] [PDF]

				N. Mounier, C. Gisselbrecht, J. Briere, C. Haioun, P. Feugier, F. Offner, C. Recher, A. Stamatoullas, F. Morschhauser, M. Macro, et al. All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) Ann. Onc., December 1, 2004; 15(12): 1790 - 1797. [Abstract] [Full Text] [PDF]

				J. O. Armitage, J. M. Vose, and D. D. Weisenburger Towards understanding the peripheral T-cell lymphomas Ann. Onc., October 1, 2004; 15(10): 1447 - 1449. [Full Text] [PDF]

				K. J. Savage, M. Chhanabhai, R. D. Gascoyne, and J. M. Connors Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification Ann. Onc., October 1, 2004; 15(10): 1467 - 1475. [Abstract] [Full Text] [PDF]

				P. Corradini, A. Dodero, F. Zallio, D. Caracciolo, M. Casini, M. Bregni, F. Narni, F. Patriarca, M. Boccadoro, F. Benedetti, et al. Graft-Versus-Lymphoma Effect in Relapsed Peripheral T-Cell Non-Hodgkin's Lymphomas After Reduced-Intensity Conditioning Followed by Allogeneic Transplantation of Hematopoietic Cells J. Clin. Oncol., June 1, 2004; 22(11): 2172 - 2176. [Abstract] [Full Text] [PDF]

				A. Gallamini, C. Stelitano, R. Calvi, M. Bellei, D. Mattei, U. Vitolo, F. Morabito, M. Martelli, E. Brusamolino, E. Iannitto, et al. Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study Blood, April 1, 2004; 103(7): 2474 - 2479. [Abstract] [Full Text] [PDF]

				J. Rodriguez, M. D. Caballero, A. Gutierrez, J. Marin, J. J. Lahuerta, A. Sureda, E. Carreras, A. Leon, R. Arranz, A. Fernandez de Sevilla, et al. High-dose chemotherapy and autologous stem cell transplantation in peripheral T-cell lymphoma: the GEL-TAMO experience Ann. Onc., December 1, 2003; 14(12): 1768 - 1775. [Abstract] [Full Text] [PDF]

				W. Y. Au, A. K. W. Lie, R. Liang, Y.-L. Kwong, C.-C. Yau, M. M. C. Cheung, K.-C. Ngan, W.-H. Lau, K.-H. Wong, H.-Y. Yiu, et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: a progress report on its value Ann. Onc., November 1, 2003; 14(11): 1673 - 1676. [Abstract] [Full Text] [PDF]

				S. Daum, R. Ullrich, W. Heise, B. Dederke, H.-D. Foss, H. Stein, E. Thiel, M. Zeitz, and E.-O. Riecken Intestinal Non-Hodgkin's Lymphoma: A Multicenter Prospective Clinical Study From the German Study Group on Intestinal Non-Hodgkin's Lymphoma J. Clin. Oncol., July 15, 2003; 21(14): 2740 - 2746. [Abstract] [Full Text] [PDF]

				N. Mounier, D. Simon, C. Haioun, P. Gaulard, C. Gisselbrecht, and I. Khouri Impact of High-Dose Chemotherapy on Peripheral T-Cell Lymphomas J. Clin. Oncol., March 1, 2002; 20(5): 1426 - 1427. [Full Text] [PDF]

				J. P. Greer, M. C. Kinney, and T. P. Loughran Jr. T Cell and NK Cell Lymphoproliferative Disorders Hematology, January 1, 2001; 2001(1): 259 - 281. [Abstract] [Full Text] [PDF]